Acrux Ltd (ASX:ACR) CEO and managing director Michael Kotsanis chats with Proactive's Tylah Tully live from the ASX Small and Mid Cap Conference in September 2024. Acrux is a specialty pharma company with a track record of developing and commercialising a pipeline of topically applied pharmaceutical products. Drawing on 25 years of experience, Acrux has marketed through licensees several products worldwide with emphasis on the US. Acrux is formulating and developing a range of topical generic products by leveraging its highly skilled workforce, on-site laboratories, GMP manufacturing suite, technical, clinical and commercial experience to bring affordable products to market. The company encourages collaboration and is well positioned to discuss commercial partnering and product development opportunities. #ProactiveInvestors #Acrux #ASX #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews